Bivalent RSV vaccine effective with favourable safety profile in infants through maternal immunization
Respiratory syncytial virus (RSV) infection is a common cause of acute lower respiratory tract disease (LRTD) and a leading cause of hospitalization in infants. In Hong Kong, the single-dose RSV prefusion F protein–based (RSVpreF) vaccine, indicated for active immunization of pregnant individuals at a gestational age of 32–36 weeks, is now available for prevention of LRTD and severe LRTD caused by RSV in infants ≤6 months of age. This article discusses the burden of RSV infections and the efficacy and safety of the RSVpreF vaccine specifically against medically attended severe RSV-associated LRTD in infants, which demonstrated an efficacy of 81.8 percent at 90 days after birth and 69.4 percent at 180 days after birth in a pivotal trial.
